Literature DB >> 7955176

Alterations in muscarinic K+ channel response to acetylcholine and to G protein-mediated activation in atrial myocytes isolated from failing human hearts.

S Koumi1, C E Arentzen, C L Backer, J A Wasserstrom.   

Abstract

BACKGROUND: A variety of previous studies have demonstrated reduced diastolic potential and electrical activity in atrial specimens from patients with heart disease. Although K+ channels play a major role in determining resting membrane potential and repolarization of the action potential, little is known about the effects of preexisting heart disease on human atrial K+ channel activity. METHODS AND
RESULTS: We characterized the inwardly rectifying K+ channel (IKI) and the muscarinic K+ channel [IK(ACh)] in atrial myocytes isolated from patients with heart failure (HF) and compared electrophysiological characteristics with those from donors (control) by the patch-clamp technique. Resting membrane potentials of isolated atrial myocytes from HF were more depolarized (-51.1 +/- 9.7 mV, mean +/- SD, n = 30 patients) than those from donors (-73.0 +/- 7.2 mV, n = 4 patients, P < .001). The action potential duration in HF was longer than that in donors. Although acetylcholine (ACh) shortened the action potential, reduced the overshoot, and hyperpolarized the atrial cell membrane in HF, these effects were attenuated compared with those observed in donors. The whole-cell membrane current slope conductance in HF was small, the reversal potential was more positive, and the sensitivity to ACh was less compared with donors. In single-channel recordings from cell-attached patches, IK1 channel conductance and gating characteristics were the same in HF and donor atria. When ACh was included in the pipette solution, IK(ACh) was activated in both groups. Single-channel slope conductance of IK(ACh) averaged 42 +/- 3 pS (n = 28) in HF and 44 +/- 2 pS (n = 4) in donors, and mean open lifetime was 1.3 +/- 0.3 milliseconds (n = 24) in HF and 1.5 +/- 0.4 milliseconds (n = 4) in donors. These values were virtually identical in the two groups (not significantly different, NS), although both single IK1 and IK(ACh) channel densities were less in HF. Channel open probability of IK(ACh) was also less in HF (4.0 +/- 1.2%, n = 24) than in donors (6.8 +/- 1.1%, n = 3, P < .01). The concentration of ACh at half-maximal activation was 0.11 mumol/L in HF and 0.03 mumol/L in donors. In excised inside-out patches, IK(ACh) from HF required higher concentrations of GTP and GTP gamma S to activate the channel compared with donors. These results suggest a reduced IK(ACh) channel sensitivity to M2 cholinergic receptor-linked G protein (Gi) in HF compared with donors.
CONCLUSIONS: Atrial myocytes isolated from failing human hearts exhibited a lower resting membrane potential and reduced sensitivity to ACh compared with donor atria. Whole-cell and single-channel measurements suggest that these alterations are caused by reduced IK1 and IK(ACh) channel density and reduced IK(ACh) channel sensitivity to Gi-mediated channel activation in HF.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955176     DOI: 10.1161/01.cir.90.5.2213

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  28 in total

1.  Targeted inactivation of alphai2 or alphai3 disrupts activation of the cardiac muscarinic K+ channel, IK+Ach, in intact cells.

Authors:  M O Sowell; C Ye; D A Ricupero; S Hansen; S J Quinn; P M Vassilev; R M Mortensen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 2.  Functional M3 muscarinic acetylcholine receptors in mammalian hearts.

Authors:  Zhiguo Wang; Hong Shi; Huizhen Wang
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

Review 3.  Report on the Ion Channel Symposium : Organized by the German Cardiac Society Working Group on Cellular Electrophysiology (AG 18).

Authors:  Niels Voigt; Fleur Mason; Dierk Thomas
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-01-08

4.  I K1 and I f in ventricular myocytes isolated from control and hypertrophied rat hearts.

Authors:  María Fernández-Velasco; Gema Ruiz-Hurtado; Carmen Delgado
Journal:  Pflugers Arch       Date:  2006-01-05       Impact factor: 3.657

5.  Role of receptor kinase in short-term desensitization of cardiac muscarinic K+ channels expressed in Chinese hamster ovary cells.

Authors:  Z Shui; I A Khan; H Tsuga; T Haga; M R Boyett
Journal:  J Physiol       Date:  1998-03-01       Impact factor: 5.182

Review 6.  Human atrial fibrillation: insights from computational electrophysiological models.

Authors:  Donald M Bers; Eleonora Grandi
Journal:  Trends Cardiovasc Med       Date:  2011-07       Impact factor: 6.677

7.  Regional distribution of hyperpolarization-activated current (If) and hyperpolarization-activated cyclic nucleotide-gated channel mRNA expression in ventricular cells from control and hypertrophied rat hearts.

Authors:  María Fernández-Velasco; Nora Goren; Gemma Benito; Javier Blanco-Rivero; Lisardo Boscá; Carmen Delgado
Journal:  J Physiol       Date:  2003-09-26       Impact factor: 5.182

8.  Adenosine-Induced Atrial Fibrillation: Localized Reentrant Drivers in Lateral Right Atria due to Heterogeneous Expression of Adenosine A1 Receptors and GIRK4 Subunits in the Human Heart.

Authors:  Ning Li; Thomas A Csepe; Brian J Hansen; Lidiya V Sul; Anuradha Kalyanasundaram; Stanislav O Zakharkin; Jichao Zhao; Avirup Guha; David R Van Wagoner; Ahmet Kilic; Peter J Mohler; Paul M L Janssen; Brandon J Biesiadecki; John D Hummel; Raul Weiss; Vadim V Fedorov
Journal:  Circulation       Date:  2016-07-26       Impact factor: 29.690

Review 9.  Cardiac strong inward rectifier potassium channels.

Authors:  Justus M B Anumonwo; Anatoli N Lopatin
Journal:  J Mol Cell Cardiol       Date:  2009-08-22       Impact factor: 5.000

10.  Cellular bases for human atrial fibrillation.

Authors:  Antony J Workman; Kathleen A Kane; Andrew C Rankin
Journal:  Heart Rhythm       Date:  2008-01-17       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.